Primary prostatic lymphoma is a rare extranodal non-Hodgkin lymphoma that frequently mimics more common prostatic conditions, leading to diagnostic delay. We report the case of a 50-year-old man with HLA-B27 positive ankylosing spondylitis receiving adalimumab who presented with a six-week history of suprapubic pain, fever, and weight loss. Initial investigations demonstrated a normal prostate-specific antigen (PSA) level and a urine culture positive for Klebsiella species. Computed tomography findings were initially interpreted as severe prostatitis with possible abscess formation. However, persistent symptoms despite antibiotic therapy and subsequent magnetic resonance imaging demonstrated extensive solid infiltrative disease involving the prostate, seminal vesicles, bladder base, and pelvic sidewalls with associated lymphadenopathy, raising suspicion for malignancy. Transperineal prostate biopsy revealed diffuse large B-cell lymphoma (DLBCL), activated B-cell subtype, with immunohistochemistry positive for CD20, PAX5, BCL2, MUM1, and MYC expression, and a Ki67 proliferative index of 80% - 90%. Staging investigations excluded distant extranodal disease, supporting the diagnosis of primary prostatic lymphoma. The patient was referred for haematology management and commenced on rituximab-based chemotherapy. This case highlights the importance of reconsidering the diagnosis in patients with presumed prostatitis who fail to improve with appropriate antimicrobial therapy, particularly when PSA levels remain normal despite extensive prostatic disease.
References
[1]
Alhamadani, M.A., Pecherkin, A. and Doyle, T. (2024) Primary Prostate Lymphoma: A Rare Presentation of Lower Urinary Tract Symptoms in Young Aged Patient. JournalofSurgicalCaseReports, 2024, rjad598. https://doi.org/10.1093/jscr/rjad598
[2]
Taleb, A., Ismaili, N., Belbaraka, R., Bensouda, A., Elghissassi, I., Elmesbahi, O., et al. (2009) Primary Lymphoma of the Prostate Treated with Rituximab-Based Chemotherapy: A Case Report and Review of the Literature. CasesJournal, 2, Article 8875. https://doi.org/10.4076/1757-1626-2-8875
[3]
Yuan, H., Li, Y., Wu, J., Zhao, Y., Feng, F., Zhao, H., et al. (2025) Exploring the Rarity: Insights into Primary Diffuse Large B-Cell Lymphoma of the Prostate from a Global Retrospective Analysis. ProstateInternational, 13, 96-102. https://doi.org/10.1016/j.prnil.2024.11.008
[4]
Cheng, J., Alwis, S.M., Papa, N., Ischia, J., Bolton, D. and Woon, D. (2025) Features and Management of Incidental Prostatic Lymphoma Obtained in Lower Urinary Tract Symptoms Surgery: A Systematic Review. Société Internationale d’Urologie Journal, 6, Article 28. https://doi.org/10.3390/siuj6020028
[5]
Jia, H., Roberson, D., Luo, X., Kovell, R.C., Hartner, L. and Harryhill, J.F. (2022) Primary Follicular Lymphoma of the Prostate Presenting with Elevated PSA and a PI-RADS 3 Lesion on MRI: A Case Report. Urology Case Reports, 45, Article ID: 102195. https://doi.org/10.1016/j.eucr.2022.102195
[6]
Ab Hamid, S., Tan, S.Y., Cheah, C.H., Gan, H.K. and Cheah, P.L. (2023) Primary Prostatic Lymphoma Presenting with Prostatomegaly. Radiology: ImagingCancer, 5, e220171. https://doi.org/10.1148/rycan.220171
[7]
Kumar, P., Rahman, K., Hussein, N., Gupta, R. and Nityanand, S. (2019) Primary Prostatic Non-Hodgkin’s Lymphoma Presenting with Features of Prostatism. Journal of Cancer Research and Therapeutics, 15, S178-S179. https://doi.org/10.4103/jcrt.jcrt_886_16
[8]
Yasmeen, S., Anwar, S., Ahmed, H., Qureshi, M. and Malik, A. (2022) Primary Prostatic Diffuse Large B-Cell Lymphoma: Case Report and Literature Review. Journal of Surgical Oncology, 125, 857-861.
[9]
Ren, M. and Liu, Y. (2021) Primary Diffuse Large B-Cell Lymphoma of the Prostate: A Case Report and Review of the Literature. JournalofMedicalCaseReports, 15, Article No. 546. https://doi.org/10.1186/s13256-021-03143-3
[10]
Petrakis, G., Vrachatis, A., Athanasiou, L., Kalliakmanis, A., Kalogeras, K., Koutoulidis, V. and Fotiadis, N. (2012) Primary Prostatic Lymphoma with Diffuse Large B-Cell and MALT Components: A Case Report. Hippokratia, 16, 280-282.
[11]
Martín, O.D., Wadskier, L.A., Quiroz, Y., Bravo, H.P., Cacciamani, G., Uma?a, P., et al. (2017) Primary Non-Hodgkin Lymphoma of the Prostate: A Case Report. Ecancermedicalscience, 11, Article No. 789. https://doi.org/10.3332/ecancer.2017.789
[12]
Imam, A.A., Selim, M., Rahman, F. and Youssef, H. (2024) Anti-TNF Alpha and Risk of Lymphoma in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Medicina, 60, Article 1156. https://doi.org/10.3390/medicina60071156
[13]
Calip, G.S., Patel, P.R. and Lund, J.L. (2018) Tumor Necrosis Factor-α Inhibitors and Risk of Non-Hodgkin Lymphoma: Population-Based Evidence. Journal of Rheumatology, 45, 1440-1446.
[14]
Song, J., Park, Y., Kim, H., and Lee, S.Y. (2025) Hematologic Malignancy Risk in Patients Exposed to TNF-α Inhibitors: A Nationwide Cohort Study. Scientific Reports, 15, Article 2096.
[15]
Askling, J., Fahrbach, K., Nordstrom, B., Ross, S., Schmid, C.H. and Symmons, D. (2011) Cancer Risk with Tumor Necrosis Factor α (TNF-α) Inhibitors: Meta-Analysis of Randomized Controlled Trials of Adalimumab, Etanercept, and Infliximab Using Patient Level Data. Pharmacoepidemiology and Drug Safety, 20, 119-130.
[16]
Deng, C., Li, W., Fei, Y., Li, Y. and Zhang, F. (2016) Risk of Malignancy in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis. ScientificReports, 6, Article No. 32063. https://doi.org/10.1038/srep32063